166 related articles for article (PubMed ID: 36260990)
1. Right in time: Mitapivat for the treatment of anemia in α- and β-thalassemia.
Musallam KM; Taher AT; Cappellini MD
Cell Rep Med; 2022 Oct; 3(10):100790. PubMed ID: 36260990
[TBL] [Abstract][Full Text] [Related]
2. The pyruvate kinase activator mitapivat reduces hemolysis and improves anemia in a β-thalassemia mouse model.
Matte A; Federti E; Kung C; Kosinski PA; Narayanaswamy R; Russo R; Federico G; Carlomagno F; Desbats MA; Salviati L; Leboeuf C; Valenti MT; Turrini F; Janin A; Yu S; Beneduce E; Ronseaux S; Iatcenko I; Dang L; Ganz T; Jung CL; Iolascon A; Brugnara C; De Franceschi L
J Clin Invest; 2021 May; 131(10):. PubMed ID: 33822774
[TBL] [Abstract][Full Text] [Related]
3. Mitapivat for sickle cell disease and thalassemia.
Pilo F; Angelucci E
Drugs Today (Barc); 2023 Mar; 59(3):125-134. PubMed ID: 36847623
[TBL] [Abstract][Full Text] [Related]
4. Pyruvate kinase activators: targeting red cell metabolism in thalassemia.
Kuo KHM
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):114-120. PubMed ID: 38066911
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in adults with non-transfusion dependent α-thalassaemia or β-thalassaemia: an open-label, multicentre, phase 2 study.
Kuo KHM; Layton DM; Lal A; Al-Samkari H; Bhatia J; Kosinski PA; Tong B; Lynch M; Uhlig K; Vichinsky EP
Lancet; 2022 Aug; 400(10351):493-501. PubMed ID: 35964609
[TBL] [Abstract][Full Text] [Related]
6. Sotatercept, a novel transforming growth factor β ligand trap, improves anemia in β-thalassemia: a phase II, open-label, dose-finding study.
Cappellini MD; Porter J; Origa R; Forni GL; Voskaridou E; Galactéros F; Taher AT; Arlet JB; Ribeil JA; Garbowski M; Graziadei G; Brouzes C; Semeraro M; Laadem A; Miteva D; Zou J; Sung V; Zinger T; Attie KM; Hermine O
Haematologica; 2019 Mar; 104(3):477-484. PubMed ID: 30337358
[TBL] [Abstract][Full Text] [Related]
7. Mitapivat improves ineffective erythropoiesis and iron overload in adult patients with pyruvate kinase deficiency.
van Beers EJ; Al-Samkari H; Grace RF; Barcellini W; Glenthøj A; DiBacco M; Wind-Rotolo M; Xu R; Beynon V; Patel P; Porter JB; Kuo KHM
Blood Adv; 2024 May; 8(10):2433-2441. PubMed ID: 38330179
[TBL] [Abstract][Full Text] [Related]
8. Unmet needs in β-thalassemia and the evolving treatment landscape.
Njeim R; Naouss B; Bou-Fakhredin R; Haddad A; Taher A
Transfus Clin Biol; 2024 Feb; 31(1):48-55. PubMed ID: 38128605
[TBL] [Abstract][Full Text] [Related]
9. Mitapivat versus Placebo for Pyruvate Kinase Deficiency.
Al-Samkari H; Galactéros F; Glenthøj A; Rothman JA; Andres O; Grace RF; Morado-Arias M; Layton DM; Onodera K; Verhovsek M; Barcellini W; Chonat S; Judge MP; Zagadailov E; Xu R; Hawkins P; Beynon V; Gheuens S; van Beers EJ;
N Engl J Med; 2022 Apr; 386(15):1432-1442. PubMed ID: 35417638
[TBL] [Abstract][Full Text] [Related]
10. Mitapivat in adult patients with pyruvate kinase deficiency receiving regular transfusions (ACTIVATE-T): a multicentre, open-label, single-arm, phase 3 trial.
Glenthøj A; van Beers EJ; Al-Samkari H; Viprakasit V; Kuo KHM; Galactéros F; Chonat S; Porter J; Zagadailov E; Xu R; Oluyadi A; Hawkins P; Gheuens S; Beynon V; Barcellini W;
Lancet Haematol; 2022 Oct; 9(10):e724-e732. PubMed ID: 35988546
[TBL] [Abstract][Full Text] [Related]
11. Transfusion suppresses erythropoiesis and increases hepcidin in adult patients with β-thalassemia major: a longitudinal study.
Pasricha SR; Frazer DM; Bowden DK; Anderson GJ
Blood; 2013 Jul; 122(1):124-33. PubMed ID: 23656728
[TBL] [Abstract][Full Text] [Related]
12. Mitapivat, a novel pyruvate kinase activator, for the treatment of hereditary hemolytic anemias.
Al-Samkari H; van Beers EJ
Ther Adv Hematol; 2021; 12():20406207211066070. PubMed ID: 34987744
[TBL] [Abstract][Full Text] [Related]
13. Profile of Luspatercept in the Treatment of Anemia in Adults with Non-Transfusion-Dependent β-Thalassemia (NTDT): Design, Development and Potential Place in Therapy.
Musallam KM; Taher AT; Kattamis A; Kuo KHM; Sheth S; Cappellini MD
Drug Des Devel Ther; 2023; 17():1583-1591. PubMed ID: 37255740
[TBL] [Abstract][Full Text] [Related]
14. β-Thalassemia: evolving treatment options beyond transfusion and iron chelation.
Langer AL; Esrick EB
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):600-606. PubMed ID: 34889443
[TBL] [Abstract][Full Text] [Related]
15. Safety and Efficacy of Mitapivat in Pyruvate Kinase Deficiency.
Grace RF; Rose C; Layton DM; Galactéros F; Barcellini W; Morton DH; van Beers EJ; Yaish H; Ravindranath Y; Kuo KHM; Sheth S; Kwiatkowski JL; Barbier AJ; Bodie S; Silver B; Hua L; Kung C; Hawkins P; Jouvin MH; Bowden C; Glader B
N Engl J Med; 2019 Sep; 381(10):933-944. PubMed ID: 31483964
[TBL] [Abstract][Full Text] [Related]
16. Preclinical transfusion-dependent humanized mouse model of beta thalassemia major.
Huo Y; McConnell SC; Ryan TM
Blood; 2009 May; 113(19):4763-70. PubMed ID: 19258591
[TBL] [Abstract][Full Text] [Related]
17. Hemoglobinization and functional availability of iron for erythropoiesis in case of thalassemia and iron deficiency anemia.
Bartels PC; Schoorl M; Schoorl M
Clin Lab; 2006; 52(3-4):107-14. PubMed ID: 16584056
[TBL] [Abstract][Full Text] [Related]
18. A correlation of erythrokinetics, ineffective erythropoiesis, and erythroid precursor apoptosis in thai patients with thalassemia.
Pootrakul P; Sirankapracha P; Hemsorach S; Moungsub W; Kumbunlue R; Piangitjagum A; Wasi P; Ma L; Schrier SL
Blood; 2000 Oct; 96(7):2606-12. PubMed ID: 11001918
[TBL] [Abstract][Full Text] [Related]
19. A phase 1 dose escalation study of the pyruvate kinase activator mitapivat (AG-348) in sickle cell disease.
Xu JZ; Conrey A; Frey I; Gwaabe E; Menapace LA; Tumburu L; Lundt M; Lequang T; Li Q; Glass K; Dunkelberger EB; Iyer V; Mangus H; Kung C; Dang L; Kosinski PA; Hawkins P; Jeffries N; Eaton WA; Lay Thein S
Blood; 2022 Nov; 140(19):2053-2062. PubMed ID: 35576529
[TBL] [Abstract][Full Text] [Related]
20. β-Thalassemia intermedia: a comprehensive overview and novel approaches.
Asadov C; Alimirzoeva Z; Mammadova T; Aliyeva G; Gafarova S; Mammadov J
Int J Hematol; 2018 Jul; 108(1):5-21. PubMed ID: 29380178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]